KROS
Keros Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | -2 | 12.51M | $133.89M | +5 | −7 |
| Q1 2026 | 72 | +4 | 12.53M | $138.59M | +8 | −4 |
| Q4 2025 | 68 | +1 | 14.80M | $301.38M | +1 | — |
| Q3 2025 | 16 | 0 | 12.05M | $190.67M | — | — |
| Q2 2025 | 13 | +1 | 9.42M | $125.76M | +2 | −1 |
| Q1 2025 | 9 | -1 | 3.92M | $39.99M | +1 | −2 |
| Q4 2024 | 10 | 0 | 4.67M | $74.00M | +1 | −1 |
| Q3 2024 | 9 | -1 | 4.72M | $274.14M | +1 | −2 |
| Q2 2024 | 10 | — | 3.52M | $160.87M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 1.19M | — | $54.29M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 1.19M | — | $54.29M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 679.58K | — | $31.06M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 679.58K | — | $31.06M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 410.48K | — | $18.76M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 410.48K | — | $18.76M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 392.96K | — | $17.96M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 370.35K | — | $16.92M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 230.00K | — | $10.51M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 175.69K | — | $8.03M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 36.28K | — | $1.66M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Marshall Wace ✦ | 22.38K | — | $1.02M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 14.30K | — | $653,510 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 149 holders, 18.56M shares, $201.20M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 1.00K sh @ 10.27 · $10,270
Open-market sales (S)
Officer · 4.49K sh · $46,151
Director · 551 sh · $5,675
Officer · 3.57K sh · $36,715
Officer · 1.22K sh · $12,595
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology